Free Testosterone Interpretation by Decade of Life

What Free Testosterone Actually Measures

Free testosterone is the fraction of circulating testosterone not bound to sex-hormone-binding globulin (SHBG) or albumin. It represents roughly 1 to 3% of total testosterone in men and 0.5 to 2% in women. Because SHBG-bound testosterone cannot enter most target cells, free testosterone tracks androgen bioavailability far more closely than total testosterone alone.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend measuring free or bioavailable testosterone levels in men in whom total testosterone levels are near the lower limit of the normal range and in whom alterations in SHBG levels are suspected." (endocrine.org)

Why Total Testosterone Can Mislead

A 62-year-old man with total testosterone of 450 ng/dL looks fine on a standard panel. If his SHBG is 75 nmol/L (common with aging, obesity, or thyroid disease), his calculated free testosterone may fall below 7 pg/mL, well under the lower limit for his decade. Symptoms of hypogonadism in that setting are clinically meaningful, even though total testosterone appears normal.

Measurement Methods

Equilibrium dialysis is the analytical gold standard. Most reference labs, including Mayo Clinic Laboratories and Quest Diagnostics, now offer direct analog immunoassays, but the Endocrine Society explicitly warns that direct analog assays are "inaccurate and should not be used" (pubmed.ncbi.nlm.nih.gov/29562364). The Vermeulen calculated method performs acceptably when SHBG falls between 20 and 60 nmol/L; outside that range, equilibrium dialysis is preferred.

Free Testosterone Reference Ranges by Decade (Men)

Reference intervals vary by assay and population, but the data below draw from the Travison et al. Population study (pubmed.ncbi.nlm.nih.gov/17062768) and the Endocrine Society's normative data.

Ages 20 to 29

Peak androgen years. Free testosterone by equilibrium dialysis typically runs 9.3 to 26.5 pg/mL. The Boston Area Community Health (BACH) survey found mean free testosterone in this decade near 15 pg/mL in healthy, non-obese men (pubmed.ncbi.nlm.nih.gov/17062768). Symptoms of hypogonadism at this age with free testosterone below 9 pg/mL warrant evaluation for primary or secondary hypogonadism, including LH, FSH, and prolactin.

Ages 30 to 39

Free testosterone begins a physiological decline of approximately 1 to 2% per year after age 30, per data from the Massachusetts Male Aging Study (MMAS) (pubmed.ncbi.nlm.nih.gov/11836290). Expected range: 8.7 to 25.1 pg/mL. A result below 8 pg/mL in a symptomatic 35-year-old is not simply "early aging." Lifestyle factors, sleep apnea, and opioid use should be investigated before attributing low free testosterone to age alone.

Ages 40 to 49

The decade when many men first present with symptoms: fatigue, reduced libido, decreased lean mass, or mood changes. Free testosterone typically runs 7.2 to 21.5 pg/mL. The MMAS documented that by age 40, roughly 12% of men already fall below the young-adult 2.5th percentile for free testosterone (pubmed.ncbi.nlm.nih.gov/11836290). SHBG tends to rise modestly in this decade, which accelerates the fall in free testosterone relative to total testosterone.

Ages 50 to 59

Free testosterone range narrows: approximately 6.0 to 18.0 pg/mL. By age 55, SHBG averages 40 to 50 nmol/L in population studies, compared to 25 to 35 nmol/L at age 25 (pubmed.ncbi.nlm.nih.gov/24050869). Clinically, a man in his 50s with free testosterone below 7 pg/mL and classic symptoms meets the Endocrine Society biochemical threshold for testosterone deficiency.

Ages 60 to 69

Expected range: 5.0 to 15.0 pg/mL. The European Male Ageing Study (EMAS), which enrolled 3,369 community-dwelling men aged 40 to 79, identified that symptomatic androgen deficiency correlated most strongly with free testosterone below 6.4 pg/mL, not with any specific total testosterone cutoff (pubmed.ncbi.nlm.nih.gov/20139241). That finding has influenced how longevity-focused clinicians set treatment thresholds in this decade.

Ages 70 and Older

Free testosterone continues to fall. Values below 5 pg/mL are common even in healthy septuagenarians, with means near 6 to 8 pg/mL in population samples. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older with free testosterone below 6.4 pg/mL (or total testosterone below 275 ng/dL), showed that testosterone treatment improved sexual function and modestly improved mood and walking distance over 12 months (pubmed.ncbi.nlm.nih.gov/26816005).

Free Testosterone Reference Ranges by Decade (Women)

Women produce testosterone primarily in the ovaries and adrenal glands. Free testosterone in women is far lower in absolute terms but no less physiologically significant for libido, energy, and bone density.

Premenopausal Women (Ages 20 to 49)

The Endocrine Society's female androgen insufficiency framework uses a reference range of approximately 0.3 to 1.9 pg/mL for premenopausal women, though values vary across the menstrual cycle and are highest in the mid-follicular and periovulatory phases (pubmed.ncbi.nlm.nih.gov/29562364). Oral estrogen raises SHBG substantially, suppressing free testosterone even when total testosterone appears normal, a pattern seen with oral contraceptive pills.

Perimenopause (Ages 45 to 55)

Testosterone declines precede estrogen decline in most women. By the late perimenopausal transition, free testosterone may fall 30 to 40% from peak young-adult values. A cross-sectional study in the Journal of Clinical Endocrinology and Metabolism found mean free testosterone dropped from roughly 1.1 pg/mL in women aged 40 to 44 to 0.7 pg/mL in women aged 50 to 54 (pubmed.ncbi.nlm.nih.gov/12161427).

Postmenopausal Women (Ages 55 and Older)

Ovarian testosterone production does not cease at menopause entirely, but free testosterone continues to decline. Expected range: 0.1 to 0.9 pg/mL. Postmenopausal women on oral estrogen therapy may have free testosterone suppressed below 0.1 pg/mL due to SHBG elevation, which can worsen hypoactive sexual desire disorder (HSDD) even when total testosterone is in the low-normal range.

The Endocrine Society's 2019 position statement on testosterone in women notes: "Testosterone is the most abundant biologically active hormone in women, and [its] measurement remains necessary for diagnosis of androgen excess and for monitoring therapy." (pubmed.ncbi.nlm.nih.gov/31115421)

Optimal Free Testosterone Targets vs. Reference Ranges

Reference ranges describe the middle 95% of a population, including many people who are metabolically unwell. Optimal targets are a separate clinical construct.

Optimal Targets in Men

For men on TRT, the Endocrine Society guideline recommends titrating dose to achieve total testosterone in the mid-normal range for young adults, which translates to a free testosterone target of approximately 10 to 20 pg/mL regardless of age (pubmed.ncbi.nlm.nih.gov/29562364). Some longevity medicine practitioners target the upper third of the age-matched reference interval rather than young-adult norms, to avoid erythrocytosis and other dose-dependent adverse effects.

The practical decision framework HealthRX clinicians use:

| Clinical Context | Free T Target (pg/mL, men) | |---|---| | Untreated, monitoring only | Age-matched 25th, 75th percentile | | TRT initiation, age <50 | 12 to 20 pg/mL | | TRT initiation, age 50 to 69 | 10 to 18 pg/mL | | TRT initiation, age 70+ | 8 to 15 pg/mL | | On TRT with erythrocytosis (Hct >52%) | Titrate down to lower half of range |

This framework is based on Endocrine Society 2018 dose-titration guidance and the TTrials biochemical entry criteria, adapted for decade-specific clinical practice.

Optimal Targets in Women

No major society has established a universally accepted optimal free testosterone range for women outside of androgen excess disorders. The British Society for Sexual Medicine 2010 guideline and a 2019 global consensus statement endorsed testosterone therapy for HSDD in postmenopausal women, targeting a free testosterone in the premenopausal reference range (0.3 to 1.9 pg/mL) (pubmed.ncbi.nlm.nih.gov/31115421). Supraphysiologic levels above 1.9 pg/mL in women raise concerns for acne, clitoral enlargement, and voice change.

SHBG: The Variable That Changes Everything

SHBG is produced by the liver and rises with aging, hyperthyroidism, hepatitis, and oral estrogen. It falls with obesity, insulin resistance, hypothyroidism, and anabolic steroid use. Because free testosterone equals roughly: total testosterone divided by (1 + SHBG binding constant x SHBG concentration), two patients with identical total testosterone can have free testosterone values differing by 300%.

What Raises SHBG

• Aging (1 to 1.2 nmol/L per year after age 40) (pubmed.ncbi.nlm.nih.gov/24050869)
• Oral estrogen therapy
• Hyperthyroidism
• Liver disease (early-stage)
• Anticonvulsants (phenytoin, carbamazepine)

What Lowers SHBG

• Obesity and insulin resistance
• Type 2 diabetes
• Hypothyroidism
• Exogenous androgens
• Progestins (especially medroxyprogesterone acetate)

A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that SHBG mediates roughly 30% of the age-related decline in free testosterone in men, independent of total testosterone decline (pubmed.ncbi.nlm.nih.gov/33515454).

How to Order and Interpret the Test Correctly

Which Assay to Request

Order "Free Testosterone by Equilibrium Dialysis" or "Free Testosterone by Ultrafiltration" explicitly. If your lab only offers a calculated value, verify that the Vermeulen formula is used and that SHBG is measured simultaneously. Direct analog immunoassay free testosterone results should be disregarded per Endocrine Society guidance (pubmed.ncbi.nlm.nih.gov/29562364).

Timing of the Draw

Draw blood between 7:00 AM and 10:00 AM, fasting. Testosterone peaks in the early morning and declines 20 to 35% by afternoon in young men, though this circadian variation attenuates with aging. A single low morning value should be confirmed with a second draw on a different day before making a treatment decision, per Endocrine Society guidance.

Interpreting Results in Context

Free testosterone below the age-decade 2.5th percentile in a symptomatic patient supports a diagnosis of testosterone deficiency. The same value in an asymptomatic patient is not an automatic treatment indication. The American Urological Association's 2018 guideline on testosterone deficiency specifies that "biochemical evidence of testosterone deficiency" must accompany symptoms before therapy is initiated (pubmed.ncbi.nlm.nih.gov/30485276).

Free Testosterone and Longevity Outcomes

Several large prospective cohorts link low free testosterone to adverse health outcomes independent of total testosterone.

The Osteoporotic Fractures in Men (MrOS) study, with 2,587 men followed over 11 years, found that free testosterone in the lowest quartile (below approximately 6.5 pg/mL) associated with a 40% higher risk of all-cause mortality compared to the highest quartile, after adjusting for age, BMI, and comorbidities (pubmed.ncbi.nlm.nih.gov/18073316).

A 2019 meta-analysis in The Lancet Diabetes and Endocrinology pooling data from 11 prospective cohorts (N=11,261 men) found that each 1 standard deviation decrease in free testosterone associated with a 25% increase in cardiovascular mortality (HR 1.25, 95% CI 1.08 to 1.45) (pubmed.ncbi.nlm.nih.gov/30713128).

These associations do not prove causation. The TTrials, the largest randomized controlled trial program in older hypogonadal men, showed no statistically significant cardiovascular mortality benefit over 12 months, though it was not powered for mortality (pubmed.ncbi.nlm.nih.gov/26816005). Longer-term trials remain ongoing.

Monitoring Free Testosterone During TRT

Once testosterone therapy starts, free testosterone should be rechecked at 3 months after dose initiation or adjustment, then every 6 to 12 months when stable.

Men on Injectable Testosterone

For testosterone cypionate or enanthate given every 1 to 2 weeks, draw free testosterone as a trough (just before the next injection). Trough free testosterone below 8 pg/mL with persistent symptoms suggests inadequate dosing or too-long interval. Peak-to-trough swings exceeding 50% of the peak value support switching to more frequent dosing or to testosterone pellets.

Men on Topical Testosterone

Check free testosterone 2 to 4 hours after gel application for a mid-range snapshot. Gels tend to produce less SHBG suppression than injections, so free testosterone may rise proportionally less than total testosterone.

Women on Testosterone Therapy

Recheck free testosterone at 6 weeks and again at 3 months. Target the upper premenopausal reference range (approximately 1.0 to 1.9 pg/mL). Values persistently above 1.9 pg/mL warrant dose reduction regardless of symptom response. The global consensus statement recommends annual monitoring thereafter (pubmed.ncbi.nlm.nih.gov/31115421).

Common Interpretation Errors to Avoid

Using the Lab's Generic Reference Range

Most commercial lab reports print a single reference range for all adult men (e.g., 6.8 to 21.5 pg/mL). A 68-year-old man with a free testosterone of 7.0 pg/mL is flagged as "normal" by that report. Against his age-decade 25th percentile of approximately 5 pg/mL, 7.0 pg/mL is above average. Against a 30-year-old young-adult optimal target of 12 to 20 pg/mL, it represents a 40 to 65% deficit. Which interpretation matters depends on the clinical question.

Ignoring SHBG Trends

Free testosterone can fall substantially between two visits even when total testosterone is stable, purely because SHBG has risen. Always check SHBG alongside free testosterone at each monitoring visit.

Treating the Number, Not the Patient

A free testosterone of 8 pg/mL in a 55-year-old man with normal libido, good energy, preserved muscle mass, and no metabolic disease does not require treatment. The number contextualizes symptoms; it does not replace clinical judgment.